For the metastatic ccRCC patients treated with VEGF-targeted therapies, Toni K et al.’s study also suggested that increased tumor cell PD-L1, or PD-L1 plus tumor CD8-positive T-cell counts, were associated with shorter survival22. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.